Search Results
Results found for "Novo Nordisk"
Posts (42)
- Novo Nordisk moves to strengthen obesity efforts
January 2022 "After securing FDA approval for Wegovy last year, Novo Nordisk is strengthening its position
- New Podcast, Sweet Structures & $2.2B GPCR Moves
tracking biased signaling in Class B GPCRs, the membrane-driven modulation of mGluR2, and a big headline, Novo Nordisk’s $2.2B deal with Septerna to develop GPCR-targeted obesity therapeutics.
- Signals in Motion: Pain, Metabolism & Terry’s Corner
Novo Nordisk’s amycretin showed up to 24% weight loss, CagriSema delivered 22.7% in Phase 3, and semaglutide
Other Pages (5)
- Maria Waldhoer: Pharmacological Fingerprints and the Limits of Bias | Dr. GPCR Ecosystem
Nordisk, and into biotech at InterAx — where the next challenge is using functional fingerprints to After running her own academic group in Graz, she spent six and a half years at Novo Nordisk in early Nordisk, putting it in an animal, and watching the effect come back exactly as predicted. After working in the US and at the University in Graz in Austria, Maria worked several years at Novo Nordisk before joining InterAx Biotech in Switzerland as their Chief Scientific Officer.
- Exploring Career Paths in GPCR Research with Dr. Jacek Mokrosiński | Dr. GPCR Ecosystem
Jacek Mokrosiński "Jacek is a Senior Scientist at Novo Nordisk specializing in molecular pharmacology Since 2021, Jacek has been working at Novo Nordisk at its research sites in the UK (Oxford) and the US
- Dr. GPCR Board | Dr. GPCR Ecosystem
My experience in basic research at several universities worldwide and early R&D at Novo Nordisk A/S allowed
